Navigation Links
Amgen to Highlight New Evolocumab (AMG 145) Data at Upcoming American Heart Association Scientific Sessions 2013
Date:11/12/2013

rom relationships may be subject to disputes between the parties or may prove to be not as effective or as safe as we may have believed at the time of entering into such relationship. Also, we or others could identify safety, side effects or manufacturing problems with our products after they are on the market. Our business may be impacted by government investigations, litigation and products liability claims. We depend on third parties for a significant portion of our manufacturing capacity for the supply of certain of our current and future products and limits on supply may constrain sales of certain of our current products and product candidate development.

In addition, sales of our products are affected by the reimbursement policies imposed by third-party payors, including governments, private insurance plans and managed care providers and may be affected by regulatory, clinical and guideline developments and domestic and international trends toward managed care and healthcare cost containment as well as U.S. legislation affecting pharmaceutical pricing and reimbursement. Government and others' regulations and reimbursement policies may affect the development, usage and pricing of our products. In addition, we compete with other companies with respect to some of our marketed products as well as for the discovery and development of new products. We believe that some of our newer products, product candidates or new indications for existing products, may face competition when and as they are approved and marketed. Our products may compete against products that have lower prices, established reimbursement, superior performance, are easier to administer, or that are otherwise competitive with our products. In addition, while we routinely obtain patents for our products and technology, the protection offered by our patents and patent applications may be challenged, invalidated or circumvented by our competitors and there can be no guarantee of our ability to ob
'/>"/>

SOURCE Amgen
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7

Related biology technology :

1. Amgen and Onyx Pharmaceuticals Announce Upcoming Data Presentations at 55th American Society of Hematology Annual Meeting
2. Amgen Presents New Data From Phase 3 Study Of Talimogene Laherparepvec In Patients With Metastatic Melanoma
3. Amgen And ShanghaiTech University Announce Plans For Amgen China R&D Center To Open On ShanghaiTech Campus
4. Amgen And Servier Complete Product Collaboration Transaction
5. Amgen Announces 2013 Third Quarter Dividend
6. Technical Briefing: Amgen, PDL BioPharma, Questcor Pharma, and BioCryst Pharma
7. Amgen And Servier Announce Product Collaboration
8. Amgen Joins BlackLine Systems, SAP for Webinar on Automating Account Reconciliations
9. Amgen And AstraZeneca Highlight Data To Be Presented At European League Against Rheumatism Annual Meeting
10. Amgen Announces Top-Line Results Of Phase 3 Talimogene Laherparepvec Trial In Melanoma
11. Amgen Announces 2013 Second Quarter Dividend
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/15/2014)... , January 15, 2014 A study has ... on the Formula 1 track could help to tackle the ... Technologies (MAT), Stowhealth (a GP surgery based in Stowmarket) and ... provider Simplyhealth. Telemetry technology, which is inspired by ...
(Date:1/15/2014)... DTS Language Services, Inc . is pleased to ... Science organizations who need document translations. Clients will now ... documents in advance with a selection of nearly 50 life ... a critical factor in clinical and scientific fields, and decrease ...
(Date:1/15/2014)... TaiGen Biotechnology Company, Limited ("TaiGen") today announced that they ... Russian pharmaceutical company, to develop and commercialize nemonoxacin (Taigexyn ... , Turkey and other members ... antibiotic for the treatment of bacterial infections including those ...
(Date:1/14/2014)... a leading provider of strategic communications services to corporations and organizations ... the United States and Europe ... is returning to the firm,s Washington, D.C. ... than two years of service as Associate Commissioner for the Office ...
Breaking Biology Technology:Formula 1 Technology Tackles Obesity in Unique Healthcare Partnership 2Formula 1 Technology Tackles Obesity in Unique Healthcare Partnership 3Formula 1 Technology Tackles Obesity in Unique Healthcare Partnership 4DTS Improves Efficiency for Life Science Document Translations 2TaiGen Biotechnology Signed Exclusive License Agreement with R-Pharm for Nemonoxacin (Taigexyn(R)) 2TaiGen Biotechnology Signed Exclusive License Agreement with R-Pharm for Nemonoxacin (Taigexyn(R)) 3TaiGen Biotechnology Signed Exclusive License Agreement with R-Pharm for Nemonoxacin (Taigexyn(R)) 4Former FDA Associate Commissioner Returns To 3D Communications 2
... a leading clinical stage biotechnology company with offices ... proprietary stem cell and tissue engineering based therapies, ... Cooperative Research and Development Agreement (CRADA) with the ... at Fort Sam Houston, Texas. The 3-year CRADA, ...
... PARK, Md., June 6, 2011 CosmosID™, a ... (TAP) incubator developing comprehensive pathogen identification technologies, ... life sciences company category during the 2011 Maryland ... (Logo: http://photos.prnewswire.com/prnh/20101005/MTECHLOGO ) In ...
... June 6, 2011 Celtaxsys, Inc., a private biopharmaceutical company ... sciences industry veteran, H. Daniel Perez, M.D., to its Board ... Dr. Perez has joined the Celtaxsys team," says Dr. Michael ... "He brings more than 25 years of high level pharmaceutical ...
Cached Biology Technology:Arteriocyte and the U.S. Army Institute of Surgical Research (USAISR) Sign a CRADA to Speed Development of Cellular Therapies for Orthopaedic Trauma 2Arteriocyte and the U.S. Army Institute of Surgical Research (USAISR) Sign a CRADA to Speed Development of Cellular Therapies for Orthopaedic Trauma 3Mtech TAP Company CosmosID™ Wins Best Life Sciences Company in the Maryland Incubator Company of the Year Awards 2Mtech TAP Company CosmosID™ Wins Best Life Sciences Company in the Maryland Incubator Company of the Year Awards 3Mtech TAP Company CosmosID™ Wins Best Life Sciences Company in the Maryland Incubator Company of the Year Awards 4Dr. H. Daniel Perez Joins Celtaxsys Board of Directors 2
(Date:7/10/2014)... 10 July 2014 Amyloid diseases, such as ... spongiform encephalopathies, all share the common trait that ... plaques. Yet in vitro studies have found that ... themselves are very toxic. New evidence using two-dimensional ... structure during the amylin aggregation pathway that may ...
(Date:7/10/2014)... 10,2014 For children and teens living with a ... contribute to decreased quality of life, reports a study ... Behavioral Pediatrics , the official journal of the ... The journal is published by Lippincott Williams & ... . , "Self-competence may function as a protective factor ...
(Date:7/10/2014)... natural-color satellite image was collected by the Moderate Resolution ... 10, 2014. Each hot spot, which appears as a ... on the MODIS instrument recognized temperatures higher than background. ... image, such hot spots are diagnostic for fire. ... little danger coming directly from the fires, although the ...
Breaking Biology News(10 mins):New technology reveals insights into mechanisms underlying amyloid diseases 2For children with pacemakers, 'self-competence' affects quality of life 2
... appointment of Esin Gulari, dean of the College of Engineering ... Science Board (NSB). President George W. Bush nominated Gulari for ... is a tremendous honor for me as a scientist and ... in a unique position to make contributions on a national ...
... 3, 2008 Case Western Reserve University School of Medicine ... The National Children,s Study, the National Institutes of Health,s comprehensive ... children,s health. At a briefing today, NIH ... one of 36 new and existing study centers which would ...
... observance of Nuclear Medicine Week (October 5 to 11) ... today a new fact sheet highlighting recent developments in ... in which breast cancer is diagnosed and treated. ... painless imaging tool for diagnosing and treating breast cancer. ...
Cached Biology News:US Senate confirms Clemson University engineering Dean Esin Gulari to National Science Board 2NIH selects Case Western Reserve University to participate in National Children's Study 2SNM releases new fact sheet on breast cancer and molecular imaging 2
... ESGRO Complete Derivation Kit is ... ES cells from delayed blastocysts in ... Clonal ... Delayed Blastocyst Incubation Medium Trypsin ...
Template and primers for preparation of internal control spots...
Reusble. Uses in conjunction with the Apoptotic Cell Isolation Kit....
ANTI K. AEROGENES...
Biology Products: